Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)
The purpose of this study is to evaluate the efficacy of nelarabine-based consolidation and maintenance therapy in term of relapse-free survival (RFS) in high-risk (HR) patients.
T-cell Adult Acute Lymphoblastic Leukemia
DRUG: nelarabine
Disease free survival (DFS), 4 years
Overall survival, 4 years|Cumulative incidence of relapse, 4 years|Non relapse mortality (NRM), 4 years|Disease free survival censored at allograft in first complete remission (CR), 4 years|Cumulative incidence of relapse censored at allograft in first complete remission (CR), 4 years|Overall survival censored at allograft in first complete remission (CR), 4 years|Non relapse mortality (NRM) censored at allograft in first complete remission (CR), 4 years|Minimal residual disease (MRD), within 1 year|Proportion of patients having received the 5 cycles of nelarabine, 3 years
The purpose of this study is to evaluate the efficacy of nelarabine-based consolidation and maintenance therapy in term of relapse-free survival (RFS) in high-risk (HR) patients.